Pancreatic Abscess

A pancreatic abscess is a localized, encapsulated collection of purulent material (neutrophils, cellular debris, and necrotic tissue) within the pancreatic parenchyma or in the peripancreatic tissues, typically arising as a sequela to severe necrotizing pancreatitis. It is a distinct entity from pancreatic pseudocysts (which lack an epithelial lining and contain sterile fluid) and infected pancreatic necrosis (which involves non-encapsulated necrotic tissue). In veterinary medicine, pancreatic abscesses are rare but life-threatening, often associated with concurrent pancreatic necrosis, bacterial translocation, and systemic inflammatory response syndrome (SIRS). The abscess may be single or multiple, and can extend into adjacent structures such as the duodenum, stomach, or mesentery. Clinically, it presents with signs of severe abdominal pain, vomiting, fever, and sepsis, and requires aggressive medical and often surgical intervention.

The primary etiology of pancreatic abscess is secondary bacterial infection of necrotic pancreatic tissue following acute necrotizing pancreatitis. The most commonly isolated bacteria include Escherichia coli, Enterococcus spp., Staphylococcus spp., Streptococcus spp., Klebsiella pneumoniae, Pseudomonas aeruginosa, and anaerobic organisms such as Bacteroides and Clostridium species. These bacteria may originate from the gastrointestinal tract via translocation across the compromised intestinal barrier, ascending infection from the biliary tract, or hematogenous spread. In some cases, pancreatic abscesses may develop as a complication of pancreatic trauma, pancreatic surgery, or percutaneous pancreatic biopsy. Fungal infections (e.g., Candida spp.) are rare but possible in immunocompromised patients. The underlying cause of pancreatitis itself may be idiopathic, dietary (high-fat meals), hyperlipidemia, hypercalcemia, drug-induced (e.g., azathioprine, L-asparaginase, potassium bromide), or associated with concurrent diseases such as diabetes mellitus, hypothyroidism, or inflammatory bowel disease. In dogs, breed predispositions (e.g., Miniature Schnauzers, Yorkshire Terriers) suggest a genetic component, while in cats, pancreatitis is often associated with hepatic lipidosis and inflammatory bowel disease.

Pancreatic abscess is an uncommon complication of pancreatitis in dogs and cats. The exact incidence is unknown, but it is estimated to occur in less than 5% of canine pancreatitis cases. It is more frequently reported in dogs than in cats. There is no strong sex predilection, but some studies suggest a slight male predominance. The condition is more common in middle-aged to older animals (median age 7-10 years). Certain breeds are overrepresented, including Miniature Schnauzers, Yorkshire Terriers, and other terrier breeds, likely due to genetic predispositions to hyperlipidemia and pancreatitis. In cats, pancreatic abscess is extremely rare, with only isolated case reports; it may occur in association with feline pancreatitis, which is often chronic and subclinical. Geographic and seasonal variations are not well-documented, but pancreatitis may be more common in animals fed high-fat diets or those with access to garbage. No specific environmental factors are known to directly cause pancreatic abscess.

The pathophysiology of pancreatic abscess begins with acute pancreatitis, which triggers premature activation of trypsinogen within the pancreatic acinar cells, leading to autodigestion of the pancreas. This results in acinar cell necrosis, hemorrhage, and inflammation. The release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) and reactive oxygen species causes local and systemic inflammation, leading to increased vascular permeability, edema, and ischemia. Necrotic pancreatic tissue becomes a nidus for bacterial colonization, particularly from the gastrointestinal tract. Bacterial translocation occurs due to disruption of the intestinal mucosal barrier, which is compromised by splanchnic hypoperfusion and ischemia. Once bacteria invade the necrotic tissue, they proliferate, forming a purulent exudate. The host's inflammatory response attempts to wall off the infection, resulting in a fibrous capsule, thus forming an abscess. The abscess can expand, causing pressure necrosis of adjacent organs, and may rupture, leading to peritonitis or sepsis. Systemic complications include SIRS, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), acute kidney injury, and multi-organ dysfunction syndrome (MODS). The presence of an abscess perpetuates a persistent inflammatory state, leading to chronic illness and poor response to medical therapy alone.

Predisposing factors for pancreatic abscess include any condition that predisposes to severe necrotizing pancreatitis. These include: (1) Dietary indiscretion, especially ingestion of high-fat meals, which triggers hypertriglyceridemia and subsequent pancreatitis. (2) Hyperlipidemia, particularly hypertriglyceridemia, which is common in Miniature Schnauzers and can be hereditary. (3) Hypercalcemia, which can be due to primary hyperparathyroidism, malignancy, or vitamin D toxicity, and can precipitate pancreatitis. (4) Drug administration, such as azathioprine, L-asparaginase, potassium bromide, phenobarbital, and certain diuretics (e.g., furosemide). (5) Concurrent endocrine diseases, including diabetes mellitus, hypothyroidism, and hyperadrenocorticism. (6) Biliary tract disease, such as cholangitis or cholecystitis, which can cause ascending infection. (7) Pancreatic trauma, including blunt abdominal trauma or surgical manipulation. (8) Pancreatic duct obstruction due to neoplasia, parasites, or strictures. (9) Immunosuppression, either from disease (e.g., feline leukemia virus, feline immunodeficiency virus) or from corticosteroid therapy, which may increase susceptibility to bacterial infection. (10) Inflammatory bowel disease, which is associated with pancreatitis in cats. (11) Genetic predisposition in certain breeds, such as Miniature Schnauzers, which have a higher risk of hyperlipidemia and pancreatitis. (12) Obesity, which is a risk factor for pancreatitis and its complications.

Clinical signs of pancreatic abscess are often severe and may be indistinguishable from severe acute pancreatitis. They include: (1) Peracute/acute stage: sudden onset of vomiting (often intractable), severe abdominal pain (manifested as restlessness, panting, or a 'praying' posture), anorexia, and lethargy. (2) Subacute/chronic stage: persistent or intermittent vomiting, weight loss, diarrhea (sometimes with melena), and a palpable abdominal mass in some cases. (3) Systemic signs: fever (in about 50% of cases), tachycardia, tachypnea, dehydration, and signs of sepsis (e.g., injected mucous membranes, prolonged capillary refill time, weak pulses). (4) Abdominal palpation may reveal a cranial abdominal mass, pain on palpation, or signs of peritonitis (e.g., guarding, fluid wave). (5) In cats, signs may be more vague, including lethargy, anorexia, and weight loss, with less pronounced vomiting and abdominal pain. (6) Jaundice may occur if the abscess compresses the common bile duct. (7) Respiratory signs (dyspnea) may develop due to pleural effusion or ARDS. (8) In terminal stages, signs of MODS may appear, including oliguria, icterus, and neurological signs (e.g., seizures) due to hepatic encephalopathy or electrolyte imbalances.

Differential diagnoses for pancreatic abscess include: (1) Acute pancreatitis without abscess: Differentiation relies on imaging (ultrasound or CT) to detect an encapsulated fluid/purulent collection; clinical signs may be identical, but abscess often causes persistent fever and lack of response to medical therapy. (2) Pancreatic pseudocyst: A sterile fluid-filled cavity with a fibrous wall; differentiation requires fluid analysis (sterile vs. infected) and culture; pseudocysts are rare in dogs and cats. (3) Pancreatic neoplasia (e.g., pancreatic adenocarcinoma): May present with a mass, weight loss, and jaundice; cytology/histopathology is definitive; imaging may show a solid mass rather than a cavitary lesion. (4) Peripancreatic abscess (e.g., from a foreign body or perforated duodenal ulcer): May mimic pancreatic abscess; imaging and exploratory surgery may be needed. (5) Cholecystitis or cholangitis: Can cause fever, vomiting, and abdominal pain; liver enzyme elevations and biliary imaging (ultrasound) help differentiate. (6) Septic peritonitis from other causes (e.g., gastrointestinal perforation): May present with acute abdomen and sepsis; abdominal fluid analysis and imaging are key. (7) Mesenteric lymphadenitis or abdominal lymphadenopathy: May cause a palpable mass; ultrasound-guided FNA can differentiate. (8) Intestinal obstruction (e.g., foreign body): Causes vomiting and abdominal pain; imaging (radiography/ultrasound) may reveal obstruction. (9) Hepatobiliary disease (e.g., hepatic abscess): May cause fever and abdominal pain; liver enzyme elevations and imaging (ultrasound) help differentiate. (10) Gastric dilation-volvulus (GDV): Presents with acute abdominal distension and shock; radiography is diagnostic.

The diagnostic algorithm for pancreatic abscess involves: (1) Initial triage: Assess vital signs, hydration status, and severity of abdominal pain. Stabilize with IV fluids and analgesics. (2) Baseline bloodwork: Complete blood count (CBC), serum biochemistry profile, and electrolytes. Look for leukocytosis with left shift, elevated liver enzymes (ALT, ALP), hyperbilirubinemia, azotemia, and electrolyte imbalances (e.g., hypokalemia, hypocalcemia). (3) Specific pancreatic biomarkers: Serum canine pancreatic lipase immunoreactivity (cPLI) or feline pancreatic lipase immunoreactivity (fPLI) is highly sensitive and specific for pancreatitis; levels >400 μg/L (dogs) or >3.5 μg/L (cats) are consistent with pancreatitis. (4) Abdominal ultrasound: This is the imaging modality of choice. Look for an encapsulated hypoechoic or mixed echogenic mass within the pancreas, with or without internal gas (suggesting anaerobic infection). Also assess for peripancreatic fluid, peritoneal effusion, and biliary obstruction. (5) If ultrasound is inconclusive or if surgery is planned, computed tomography (CT) may be performed; CT provides better delineation of the abscess and its extent. (6) Ultrasound-guided fine-needle aspiration (FNA) of the abscess for cytology and bacterial culture and sensitivity is recommended to confirm the diagnosis and guide antimicrobial therapy. (7) If FNA is not feasible or if the patient deteriorates, exploratory laparotomy may be necessary for diagnosis and treatment. (8) Additional tests: Blood cultures, coagulation profile (to assess for DIC), and thoracic radiographs (to rule out metastatic infection or pleural effusion). (9) In cats, consider testing for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) if immunosuppression is suspected.

Laboratory findings in pancreatic abscess are consistent with severe pancreatitis and sepsis. (1) Hematology: Leukocytosis with a left shift (neutrophilia with band neutrophils) is common; leukopenia may occur in severe sepsis. Toxic neutrophils may be seen. Anemia may develop due to chronic disease or blood loss. Thrombocytopenia may indicate DIC. (2) Serum biochemistry: Elevated liver enzymes (ALT, ALP) due to hepatic inflammation or biliary obstruction. Hyperbilirubinemia may occur if the abscess compresses the bile duct. Azotemia (elevated BUN and creatinine) may be due to prerenal (dehydration) or renal (acute kidney injury) causes. Hyperglycemia may occur due to stress or diabetes mellitus; hypoglycemia can occur in severe sepsis. Hypertriglyceridemia and hypercholesterolemia are common in dogs with pancreatitis. Hypocalcemia (ionized calcium <1.0 mmol/L) is a negative prognostic indicator. Hypokalemia and hyponatremia may occur due to vomiting and fluid loss. (3) Urinalysis: May show glucosuria, proteinuria, or casts if renal injury is present. Urine specific gravity may be low if renal failure is present. (4) Blood gas analysis: Metabolic acidosis is common due to lactic acidosis from hypoperfusion. (5) Specific biomarkers: cPLI or fPLI is elevated. C-reactive protein (CRP) may be elevated as an inflammatory marker. Procalcitonin may be used in some settings. (6) Coagulation profile: Prolonged PT and aPTT, elevated D-dimers, and decreased antithrombin III indicate DIC. (7) Serology/PCR: Not routinely performed for bacterial abscess, but blood cultures may be positive in septic patients. (8) Endocrine assays: If concurrent endocrinopathy is suspected, measure thyroid hormones, cortisol, or insulin.

Imaging is crucial for diagnosis and management. (1) Abdominal radiography: May show a soft tissue mass in the cranial abdomen, loss of serosal detail (due to peritonitis), or gas bubbles in the pancreatic region (suggestive of gas-forming bacteria). However, radiography is non-specific and often normal. (2) Abdominal ultrasonography: This is the primary imaging modality. Findings include a well-defined, encapsulated hypoechoic or complex mass within the pancreatic region, often with internal echogenic debris or gas. The pancreas may be enlarged and hypoechoic. Peripancreatic fluid or peritoneal effusion may be present. Doppler ultrasound can assess vascularity. Ultrasound is also useful for guiding FNA. (3) Computed tomography (CT): CT provides superior anatomical detail and is excellent for detecting abscesses, especially if they are small or located in the pancreatic body or tail. Contrast-enhanced CT can differentiate necrotic tissue from viable tissue. CT is particularly useful for surgical planning. (4) Magnetic resonance imaging (MRI): MRI is rarely used in veterinary medicine for pancreatic abscess but can provide excellent soft tissue contrast. (5) Endoscopic retrograde cholangiopancreatography (ERCP): Not commonly performed in veterinary patients but can be used to evaluate the pancreatic duct. (6) Fluoroscopy: May be used during interventional procedures such as percutaneous drainage. (7) Echocardiography: Not directly relevant, but may be performed to assess for endocarditis if sepsis is suspected.

Cytological and histopathological evaluation is essential for definitive diagnosis. (1) Fine-needle aspiration (FNA) of the abscess: Cytology typically reveals a highly cellular sample with degenerate neutrophils, necrotic debris, and bacteria (intracellular and extracellular). Gram stain can help identify bacterial morphology. Culture and sensitivity should be performed on the aspirate. (2) Fluid analysis: If the abscess is drained, the fluid is typically purulent, with a high protein content and a nucleated cell count >30,000 cells/μL, predominantly neutrophils. (3) Histopathology: If surgical biopsy is obtained, histopathology shows a well-demarcated area of necrosis with a thick fibrous capsule, surrounded by inflammatory infiltrate (neutrophils, macrophages, lymphocytes, plasma cells). There may be evidence of chronic pancreatitis with fibrosis and acinar atrophy. Special stains (e.g., Gram stain, silver stain) can identify bacteria or fungi. (4) Immunohistochemistry: May be used to identify specific pathogens (e.g., Toxoplasma, Neospora) if infectious causes are suspected, though these are rare.

Treatment of pancreatic abscess requires aggressive medical management and often surgical intervention. (1) Emergency stabilization: IV fluid resuscitation with isotonic crystalloids (e.g., Lactated Ringer's solution) at shock doses (e.g., 20-30 mL/kg bolus in dogs, 10-20 mL/kg in cats) followed by maintenance rates (e.g., 60-90 mL/kg/day in dogs, 40-60 mL/kg/day in cats) with adjustments based on hydration and losses. Colloids (e.g., hydroxyethyl starch) may be used if hypoproteinemia is present. (2) Analgesia: Opioids are the mainstay, e.g., buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl CRI (2-5 μg/kg/h). (3) Antimicrobial therapy: Broad-spectrum antibiotics are indicated because the abscess is infected. Initial choice should cover Gram-negative, Gram-positive, and anaerobic bacteria. A common protocol is ampicillin (22 mg/kg IV q8h) or amoxicillin-clavulanate (22 mg/kg PO/IV q12h) combined with enrofloxacin (10 mg/kg IV/PO q24h) and metronidazole (15 mg/kg IV/PO q12h). Adjust based on culture and sensitivity. (4) Antiemetics: Maropitant (1 mg/kg IV/SC q24h) or ondansetron (0.5-1 mg/kg IV q12h) to control vomiting. (5) Gastrointestinal protectants: Proton pump inhibitors (e.g., pantoprazole 1 mg/kg IV q12h) or H2 blockers (e.g., famotidine 0.5 mg/kg IV/PO q12h) to reduce gastric acid secretion. (6) Nutritional support: Early enteral nutrition is recommended if the patient is stable; a jejunostomy tube or nasojejunal tube may be placed to bypass the stomach. If enteral feeding is not possible, parenteral nutrition may be considered. (7) Surgical intervention: Surgical drainage (marsupialization or omentalization) or surgical resection of the abscess is often necessary, especially if the abscess is large, ruptured, or unresponsive to medical therapy. Percutaneous drainage under ultrasound or CT guidance may be an alternative in selected cases. (8) Supportive care: Monitor for DIC, acute kidney injury, and ARDS. Administer fresh frozen plasma if coagulopathy is present. (9) Management of underlying causes: Address hyperlipidemia, hypercalcemia, or drug-induced causes. (10) In cats, consider additional therapy for concurrent diseases such as hepatic lipidosis or inflammatory bowel disease.

The prognosis for pancreatic abscess is guarded to poor. Mortality rates are high, ranging from 30% to 50% in dogs, even with aggressive treatment. Negative prognostic indicators include: (1) Presence of septic peritonitis or rupture of the abscess. (2) Multi-organ dysfunction syndrome (MODS). (3) Disseminated intravascular coagulation (DIC). (4) Hypocalcemia (ionized calcium <1.0 mmol/L). (5) Severe leukopenia or leukocytosis with a marked left shift. (6) Lack of response to medical therapy within 48-72 hours. (7) Presence of concurrent diseases such as diabetes mellitus or hyperadrenocorticism. (8) Advanced age. (9) In cats, the prognosis is even more guarded due to the frequent presence of concurrent diseases. However, with early surgical intervention and appropriate antimicrobial therapy, some patients can recover. Long-term complications may include chronic pancreatitis, exocrine pancreatic insufficiency, and diabetes mellitus. Recurrence of abscess is possible but uncommon.

Follow-up care is critical for monitoring recovery and detecting complications. (1) Re-check examinations: Initially, patients should be re-evaluated daily during hospitalization. After discharge, re-check at 1 week, 2 weeks, 1 month, and then every 3-6 months. (2) Serial laboratory monitoring: CBC, serum biochemistry, and electrolytes should be repeated at each re-check. cPLI or fPLI may be monitored to assess resolution of pancreatitis. (3) Imaging: Abdominal ultrasound should be repeated at 2-4 weeks post-treatment to confirm resolution of the abscess and to monitor for recurrence or complications such as pseudocyst formation. (4) Nutritional management: A low-fat, highly digestible diet is recommended long-term. In dogs, a diet with <10% fat on a dry matter basis is often advised. In cats, a moderate-fat diet may be more appropriate. (5) Medication adjustments: If the patient is on long-term medications (e.g., pancreatic enzyme supplements, insulin), adjust dosages based on clinical response and laboratory values. (6) Monitoring for complications: Watch for signs of exocrine pancreatic insufficiency (weight loss, diarrhea, steatorrhea) and diabetes mellitus (polyuria, polydipsia, hyperglycemia). (7) Owner education: Instruct owners to avoid high-fat treats and table scraps, and to monitor for recurrence of clinical signs. (8) In cases of surgical drainage, monitor the surgical site for infection or dehiscence.

Pearls: (1) Always consider pancreatic abscess in any patient with acute pancreatitis that fails to improve within 48-72 hours of appropriate medical therapy. (2) Early ultrasound is essential; if a mass is seen, perform FNA for cytology and culture. (3) Broad-spectrum antibiotics should be started immediately, but de-escalate based on culture results. (4) Surgical drainage is often necessary; do not delay surgery if the patient is deteriorating. (5) Provide aggressive nutritional support; early enteral nutrition improves outcomes. (6) Monitor ionized calcium; hypocalcemia is a poor prognostic indicator. (7) In cats, pancreatitis may be chronic and subclinical; a high index of suspicion is needed. Pitfalls: (1) Do not use corticosteroids to treat pancreatitis; they are contraindicated and may worsen infection. (2) Avoid overuse of NSAIDs; they can cause gastrointestinal ulceration and renal injury. (3) Do not rely solely on medical therapy; if an abscess is present, it will not resolve without drainage. (4) Do not delay surgery in septic patients; early intervention improves survival. (5) Do not forget to check for concurrent diseases such as hyperlipidemia, hypercalcemia, or endocrinopathies. (6) Do not use oral antibiotics in a vomiting patient; use parenteral routes. (7) Do not ignore the possibility of fungal infection in immunocompromised patients.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for pancreatic abscess: (1) Antimicrobials: (a) Ampicillin: 22 mg/kg IV q8h; or Amoxicillin-clavulanate: 22 mg/kg PO/IV q12h. (b) Enrofloxacin: 10 mg/kg IV/PO q24h (dogs); 5 mg/kg IV/PO q24h (cats). (c) Metronidazole: 15 mg/kg IV/PO q12h (dogs); 10 mg/kg IV/PO q12h (cats). (d) Alternative: Cefoxitin: 30 mg/kg IV q8h. (e) If anaerobic infection is suspected, add clindamycin: 11 mg/kg IV/PO q12h. (f) Adjust dosages in renal impairment: e.g., enrofloxacin dose interval may need to be extended. (2) Analgesics: (a) Buprenorphine: 0.01-0.02 mg/kg IV/IM q8-12h. (b) Fentanyl CRI: 2-5 μg/kg/h IV. (c) Hydromorphone: 0.1-0.2 mg/kg IV/IM q4-6h. (3) Antiemetics: (a) Maropitant: 1 mg/kg IV/SC q24h (dogs); 1 mg/kg IV/SC q24h (cats). (b) Ondansetron: 0.5-1 mg/kg IV q12h. (c) Metoclopramide CRI: 1-2 mg/kg/day IV. (4) Gastrointestinal protectants: (a) Pantoprazole: 1 mg/kg IV q12h. (b) Famotidine: 0.5 mg/kg IV/PO q12h. (c) Sucralfate: 0.5-1 g PO q8h (dogs); 0.25-0.5 g PO q8h (cats). (5) Nutritional support: (a) Enteral feeding via jejunostomy tube: use a liquid diet such as Clinicare Canine/Feline Liquid Diet. (b) Parenteral nutrition: if enteral not possible, use a lipid-free formulation initially. (6) Supportive care: (a) Fresh frozen plasma: 10-20 mL/kg IV if coagulopathy. (b) Heparin: 75-150 IU/kg SC q8h for DIC. (c) Insulin therapy if diabetes mellitus develops: regular insulin 0.1-0.2 U/kg IV initially, then adjust. (7) Antifungals: If fungal infection is confirmed, use fluconazole (5-10 mg/kg PO q12h) or amphotericin B (0.5-1 mg/kg IV q48h). (8) Contraindications: Avoid corticosteroids, NSAIDs, and drugs that may exacerbate pancreatitis (e.g., azathioprine, L-asparaginase).

Evidence-based literature on pancreatic abscess in veterinary medicine is limited to case reports and small case series. Key studies include: (1) A retrospective study by Hess et al. (1998) on 70 dogs with acute pancreatitis, which identified pancreatic abscess in 5% of cases and reported a mortality rate of 50%. (2) A case series by Simpson et al. (1994) described successful surgical management of pancreatic abscess in three dogs using omentalization. (3) A study by Mansfield et al. (2008) evaluated the use of cPLI in diagnosing pancreatitis and its complications, noting that persistent elevation may indicate abscess formation. (4) A review by Xenoulis and Steiner (2008) on canine pancreatitis highlighted the importance of early imaging and surgical intervention for abscesses. (5) In cats, a case report by Saunders et al. (2002) described a pancreatic abscess in a cat with concurrent inflammatory bowel disease, treated successfully with surgery and antibiotics. (6) Consensus guidelines from the ACVIM (2012) on pancreatitis in dogs and cats recommend that pancreatic abscess be treated with surgical drainage and broad-spectrum antibiotics. (7) A recent study by Cridge et al. (2020) evaluated the use of CT in diagnosing pancreatic abscesses in dogs, showing that CT had higher sensitivity than ultrasound. (8) A meta-analysis by Páramo et al. (2019) on human pancreatic abscess management supports early percutaneous drainage or surgical debridement, which may be extrapolated to veterinary patients. Overall, the evidence is of low quality, but it supports aggressive management with surgery and appropriate antimicrobial therapy.